GSK moves to dismiss Moderna counterclaims in US vaccine patent suit
GlaxoSmithKline responded to Moderna’s counterclaims in a pair of US patent infringement suits over the Covid and RSV vaccines with a motion-to-dismiss for failure to state a claim.Pharma giant GlaxoSmithKline filed...To view the full article, register now.
Already a subscriber? Click here to view full article